Pancreatic adenocarcinoma (PDA) is the fourth cause of cancer-related death, having a five-years survival rate of 8% [1]. The therapeutic approach to advanced unresectable PDA is systemic cytotoxic chemotherapy. FOLFIRINOX regimen is currently used as first-line systemic treatment in advanced PDA, showing a significant improvement in terms of survival compared to gemcitabine in metastatic pancreatic cancer (MPC), whereas similar results have not yet been proven in locally advanced pancreatic cancer (LAPC) [2]. Contrast-enhanced CT (CECT) is the conventional imaging modality for response assessment in this...

Institutional review board approval and waiver for informed consent was obtained for this retrospective study. Patients A computer search in our hospital database was performed, identifying patients with unresectable PDA treated with FOLFIRINOX regimen between November 2010 and February 2017. Inclusion criteria were as follows: (1) histological evidence of PDA; (2) unresectability of the pancreatic primary tumour established by a gastro-intestinal multidisciplinary team; (3) FOLFIRINOX therapy duration of at least 1 month or 2 cycles; (4) baseline CECT study including a portal-venous scan of thorax-abdomen-pelvis...

A total of 32 LAPC patients and 35 MPC patients were enrolled in this study. According to RECIST 1.1 criteria, in the LAPC group, responders were 12/32 (37.5%) and non-responders were 20/32 (62.5%) and in the MPC group, responders were 12/35 (34.3%) and non-responders were 23/32 (65.7%). In both LAPC and MPC, CTTA metrics registered at BL and FA showed no significant differences between responders and non-responders. In the LAPC group, a significant difference (p < 0.001) between responders and non-responders was found for percentage...

Radiological follow-up of cytotoxic systemic treatment for PDA is currently sustained by dimensional criteria that don’t take into account intra-lesional structural changes treatment-related that could reflect drug efficacy. The aim of this study was to explore the potential relationship between CTTA metrics and their changes throughout therapy follow-up with response categorization by RECIST 1.1. According to our preliminary results, CTTA metrics values measured at BL and FA showed no significant difference between responders and non-responders by RECIST 1.1 in both LAPC and MPC groups and...

Dr. Edoardo Raimondi Radiology Registrar - University of Ferrara - Italy Clinical Research Fellow - The Royal Marsden Hospital - London - UK [email protected]

Siegel RL, Miller KD, Jemal A (2016) Cancer Statistics, 2016, CA CANCER J CLIN 2016;66:7–30 Conroy T, Desseigne F, Ychou M et al, (2011) FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, N Engl J Med 2011;364:1817-25. Eisenhauer EA, Therasse P, Bogaerts J et al, (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer 45 (2009) 228–247 Chatterjee D, Katz MH, Rashid A et al, (2011), Histologic Grading the Extent of Residual Carcinoma Following Neoadjuvant Chemoradiation in Pancreatic...